News AstraZeneca builds in obesity with $2bn+ Eccogene deal AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist
News AZ claims EU okay for Imfinzi in bladder cancer AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face